Opinion|Videos|June 4, 2025
Novel Treatment Options for Bronchiectasis
Panelists discuss how emerging DPP1 inhibitor therapies target neutrophil serine proteases to reduce neutrophilic inflammation and neutrophil extracellular trap formation in bronchiectasis.
Advertisement
Episodes in this series
Clinical Brief: Emerging Therapies for Bronchiectasis
Main Discussion Topics
- DPP1 inhibitors target neutrophil inflammation in bronchiectasis.
- Eosinophilic bronchiectasis (approximately 30% of cases) benefits from targeted therapies.
- Approaches to treatment vary based on inflammatory phenotype.
Key Points for Physicians
- DPP1 inhibitors:
- Target abnormal neutrophil function and reduce neutrophil serine proteases
- May prevent formation of neutrophil extracellular traps
- Aim to reduce exacerbations and disease progression
- For eosinophilic bronchiectasis (30% of cases):
- Inhaled corticosteroids are beneficial
- Anti-IL5 therapies show promise
- Biologic therapies are being investigated
- Discourage inhaled corticosteroids in neutrophilic bronchiectasis (70% of cases) due to potential infection risk.
Notable Insights
Peripheral eosinophil counts may help guide treatment decisions similar to their use in chronic obstructive pulmonary disease management, with different thresholds being investigated.
Clinical Significance
Emerging therapies targeting specific inflammatory pathways show promise for more precise treatment of bronchiectasis based on inflammatory phenotype.
Advertisement
Related to this article
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
2
Nearly a Decade After CAR T, Medicare’s Cell and Gene Therapy Payment Gap Persists
3
Twice-Daily Deuruxolitinib Outperformes Once-Daily in Severe AA
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5